Incyte Corporation INCY
116.26 USD -1.54 (-1.31%)
As ofNov 19, 2026, 2:42 PM EST
115.50 Day range 117.98
90.30 52-week range 129.93
- YTD
- +17.71%
- 1 year
- +14.75%
News
seekingalpha.com Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript
zacks.com INCY Wins European Commission Nod For Skin Disease Drug Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.
seekingalpha.com Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
reuters.com Incyte says EU approves oral treatment for chronic skin disease Incyte says EU approves oral treatment for chronic skin diseasebenzinga.com STOP-HS1 And STOP-HS2 Trials Evaluating Safety And Efficacy Of Povofortay In Patients With Moderate To Severe HS Met The Primary Endpoint The overall safety profile of Povofortay over 54 weeks was consistent with previously reported data; both doses were well tolerated, with no new or unexpected safety signals. The most frequent TEAEs…
businesswire.com Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa.
defenseworld.net Incyte Corporation $INCY Stock Position Cut by Eurizon Capital SGR S.p.A. Eurizon Capital SGR S.p.A. decreased its position in Incyte Corporation (NASDAQ: INCY) by 13.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange…benzinga.com Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal Cancer Trial designed to improve outcomes through Signatera™-guided Treatment on MRD (TOMR), identifying high-risk patients for curative-intent treatmentNatera, Inc. (NASDAQ:NTRA), a global leader in…
benzinga.com Leerink Partners Maintains Outperform on Incyte, Lowers Price Target to $150 Leerink Partners analyst Andrew Berens maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $154 to $150.
benzinga.com $1000 Invested In Incyte 20 Years Ago Would Be Worth This Much Today Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.34% on an annualized basis producing an average annual return of 17.11%. Currently, Incyte has a market capitalization of…benzinga.com Incyte To Present New Data On Its 30 Abstracts At American Society Of Hematology Annual Meeting Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology…
benzinga.com Bernstein Maintains Market Perform on Incyte, Raises Price Target to $108 Bernstein analyst Jeffrey Walch maintains Incyte (NASDAQ:INCY) with a Market Perform and raises the price target from $104 to $108.
benzinga.com Wells Fargo Maintains Equal-Weight on Incyte, Lowers Price Target to $127 Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and lowers the price target from $128 to $127.
benzinga.com RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $117 RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $114 to $117.
benzinga.com Barclays Maintains Overweight on Incyte, Raises Price Target to $143 Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $139 to $143.
benzinga.com This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.benzinga.com Evercore ISI Group Maintains In-Line on Incyte, Raises Price Target to $127 Evercore ISI Group analyst Maneka Mirchandaney maintains Incyte (NASDAQ:INCY) with a In-Line and raises the price target from $125 to $127.
benzinga.com Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.benzinga.com Oppenheimer Upgrades Incyte to Outperform, Raises Price Target to $144 Oppenheimer analyst Jay Olson upgrades Incyte (NASDAQ:INCY) from Perform to Outperform and raises the price target from $120 to $144.
benzinga.com Incyte Q3 2026 Earnings Call Transcript Incyte (NASDAQ:INCY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Incyte Raises FY2026 Sales Guidance from $5.130B-$5.260B to $5.210B-$5.300B vs $5.929B Est Incyte (NASDAQ:INCY) raises FY2026 sales outlook from $5.130 billion-$5.260 billion to $5.210 billion-$5.300 billion vs $5.929 billion estimate.
benzinga.com Incyte Q3 Adj. EPS $(3.60) Beats $(3.85) Estimate, Sales $1.557B Beat $1.470B Estimate Incyte (NASDAQ:INCY) reported quarterly losses of $(3.60) per share which beat the analyst consensus estimate of $(3.85) by 6.49 percent. This is a 259.29 percent decrease over earnings of $2.26 per…
benzinga.com Genmab's Encouraging Oncology Data Boosts Investor Optimism Genmab shares positive petosemtamab trial data across multiple solid tumors at ESMO and partners with Incyte on targeted colorectal therapy.benzinga.com TD Cowen Maintains Buy on Incyte, Raises Price Target to $140 TD Cowen analyst Tara Bancroft maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $138 to $140.
finance.yahoo.com Quantinuum Inc. (QNT) Quantinuum reported $98 million in quarterly bookings, 233% year-over-year revenue growth, and higher full-year revenue guidance. Its Japan expansion with RIKEN and SoftBank strengthens the company’s…
finance.yahoo.com Cerebras Systems Inc. (CBRS) Cerebras reported strong third-quarter growth and raised 2026 revenue guidance, supported by Microsoft and other hyperscaler agreements. The central execution risk remains delayed customer…
finance.yahoo.com Keel Infrastructure Corp. (KEEL) KEEL is transitioning from Bitcoin mining toward artificial-intelligence and high-performance-computing data centers. The pivot has removed most cryptocurrency treasury exposure, but leasing delays,…
ca.finance.yahoo.com Robinhood Markets, Inc. HOOD Stock Forecast & Price Target At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
ca.finance.yahoo.com Viavi Solutions Inc. VIAV Stock Forecast & Price Target At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
finance.sina.com.cn 因塞特医疗收跌1.08%,成交额1.43亿美元 该公司业务涵盖三个治疗领域:血液学、肿瘤学及炎症与自身免疫性疾病。该公司的血液学领域产品包括四款获批药物,JAKAFI(芦可替尼)、ICLUSIG(波罗替尼)、MONJUVI(塔西姆单抗-CXIX)/MINJUVI(塔西姆单抗)及NIKTIMVO(阿沙替尼),以及多项临床开发项目。该公司的肿瘤学领域则拥有两款获批药物,PEMAZYRE(培米替尼)和ZYNYZ(雷利度胺),同时推进多条临床研发管线。
finance.yahoo.com HALO Stock Hits Over 3-Month Lows, As German Court Overturns Temporary Ban On Merck’s Keytruda SC Halozyme said it would immediately file a patent infringement lawsuit against Merck in Germany, seeking permanent relief ...
finance.yahoo.com Should You Pick Vertex Stock Over Its Biotech Rivals? Vertex Pharmaceuticals (VRTX) earns the widest operating margin in a group of four biotech companies that also includes ...
finance.yahoo.com What Are Wall Street Analysts' Target Price for Incyte Stock? Incyte has outperformed the broader market, while raised guidance, positive pipeline developments, and bullish analyst ...
fidelity.co.uk Incyte Corp (INCY) Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with ...
crowdfundinsider.com Tether Invests in Stablecoin, Trading Platform SCRYPT Tether has invested in digital asset firm SCRYPT, according to a release. SCRYPT is described as one of Switzerland’s largest ...
crowdfundinsider.com Anthropic IPO to Raise Over $80 Billion at $1.5 Trillion Valuation The Anthropic IPO is a record-breaking event, topping the fairly recent SpaceX IPO in value. It also reflects a shift toward waiting as long as possible to go ...
ad-hoc-news.de Incyte stock: Company halts planned Phase 3 ovarian study Incyte is a Delaware biopharmaceutical company developing medicines through clinical programs. Its portfolio includes ...
msn.com What are Wall Street analysts' target price for Incyte stock? Headquartered in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes treatments for patients with unmet medical needs.
marketwatch.com Incyte Corp. stock outperforms competitors despite losses on the day Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with…
theglobeandmail.com Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Henry Schein (HSIC) Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte and Henry Schein . Incyte (INCY) In ...
crowdfundinsider.com Here’s Why XRP Price and Altcoins Like Avalanche (AVAX), Cardano (ADA), DogeCoin (DOGE) Will Not Fully Recover or Reach All-Time Highs Many crypto traders and investors across X and other social media platforms have been really disappointed in the performance (or lack thereof) of XRP and ...
crowdfundinsider.com Nvidia ($NVDA) Fallout May Lead to AI and Digital Assets Investors Adopting More Sophisticated Capital Allocation Strategies in 2027 The challenges faced by Nvidia (NASDAQ: NVDA) and its former CEO Jensen Huang highlight the increasingly fragile and volatile ...
